Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Carolina Salinas-Souza"'
Autor:
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently nee
Externí odkaz:
https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b
Autor:
Michele Moschetta, T. Hedley Carr, Robert McEwen, Alison M. Schram, Myria Nikolaou, Sarat Chandarlapaty, José Baselga, Gaia Schiavon, Funda Meric-Bernstam, Lillian M. Smyth, David M. Hyman, Andrea Li Ann Wong, Joana Hauser, Rhiannon Maudsley, Justin P.O. Lindemann, Iben Spanggaard, Andrew Foxley, Helen Ambrose, Pedram Razavi, Udai Banerji, Elza C. de Bruin, Carolina Salinas-Souza, Komal Jhaveri, Peter Kabos, Gerald Batist, Ana Lluch, Andrea Varga
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed. This
Autor:
Carolina Salinas-Souza, Alini Trujillo-Paolillo, Indhira Dias-Oliveira, Antonio Sergio Petrilli, Silvia Regina Caminada de Toledo
Publikováno v:
Journal of Adolescent and Young Adult Oncology. 9:621-627
Purpose: Osteosarcoma is the malignant bone tumor most common in children and adolescents. Many cytochrome P-450 (CYP) members detoxify anticancer drugs used in osteosarcoma treatment, and thus, th...
Autor:
Gareth Griffiths, Satinder Jagdev, Christine Stephens, Amit Bahl, Simon J. Crabb, Charlotte Westbury, Michelle Light, Satish Kumar, Ellice Marwood, Denise Dunkley, Carolina Salinas-Souza, Tony Elliott, Angus Robinson, Santhanam Sundar, Emily C. Shaw, Josh Northey, Amy Whitehead, Karen Martin, Alison Birtle, Robert Jones, Nichola Downs, Sam Wilding, Claire Rooney, Vincent Khoo
Publikováno v:
Journal of Clinical Oncology
PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS AND METHODS ProCAID was a placebo controlled randomized phase II trial i
Autor:
José Baselga, Andrew Foxley, Sarat Chandarlapaty, Michele Moschetta, Robert McEwen, David M. Hyman, Alan Barnicle, Iben Spanggaard, Martine P. Roudier, Elza C. de Bruin, Alison M. Schram, Gerald Batist, Joana Hauser, Ana Lluch, Pedram Razavi, Gaia Schiavon, T. Hedley Carr, Udai Banerji, Lillian M. Smyth, Funda Meric-Bernstam, Andrea Varga, Helen Ambrose, Peter Kabos, Justin P.O. Lindemann, Andrea Li Ann Wong, Rhiannon Maudsley, Carolina Salinas-Souza
Publikováno v:
Cancer Research. 80:P1-19
Background: Loss of function in the tumor suppressor gene, PTEN, activates PI3K/AKT signaling, driving tumor growth. Somatic mutations in PTEN occur in 5-10% of estrogen-receptor-positive (ER+) breast cancer (BC), and PTEN loss/inactivation is associ
Autor:
Esther H, Lips, Tapsi, Kumar, Anargyros, Megalios, Lindy L, Visser, Michael, Sheinman, Angelo, Fortunato, Vandna, Shah, Marlous, Hoogstraat, Emi, Sei, Diego, Mallo, Maria, Roman-Escorza, Ahmed A, Ahmed, Mingchu, Xu, Alexandra W, van den Belt-Dusebout, Wim, Brugman, Anna K, Casasent, Karen, Clements, Helen R, Davies, Liping, Fu, Anita, Grigoriadis, Timothy M, Hardman, Lorraine M, King, Marielle, Krete, Petra, Kristel, Michiel, de Maaker, Carlo C, Maley, Jeffrey R, Marks, Brian A, Menegaz, Lennart, Mulder, Frank, Nieboer, Salpie, Nowinski, Sarah, Pinder, Jelmar, Quist, Carolina, Salinas-Souza, Michael, Schaapveld, Marjanka K, Schmidt, Abeer M, Shaaban, Rana, Shami, Mathini, Sridharan, John, Zhang, Hilary, Stobart, Deborah, Collyar, Serena, Nik-Zainal, Lodewyk F A, Wessels, E Shelley, Hwang, Nicholas E, Navin, P Andrew, Futreal, Alastair M, Thompson, Jelle, Wesseling, Marja, van Oirsouw
Publikováno v:
Nature genetics. 54(6)
Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive disease. A fundamental biologic question is whether the invasive diseas
Autor:
Deborah Collyar, Abeer M Shaaban, Tapsi Kumar, Mingchu Xu, Angelo Fortunato, Lorraine M. King, Marlous Hoogstraat, Sarah E Pinder, Nicholas N. Navin, Wim Brugman, Andrew Futreal, Maria Roman-Escorza, Marielle Krete, Mathini Sridharan, Alastair M. Thompson, Emi Sei, Anargyros Megalios, Diego Mallo, Jelle Wesseling, Frank Nieboer, Carolina Salinas-Souza, Michael Sheinman, Hilary Stobart, Lodewyk F. A. Wessels, Rana Shami, Ahmed A. Ahmed, Esther H. Lips, Jeffrey R. Marks, Serena Nik-Zainal, Lennart Mulder, Carlo C. Maley, Helen Davies, Salpie Nowinski, Vandna Shah, John Zhang, Karen Clements, Jelmar Quist, Michael Schaapveld, E. Shelley Hwang, Petra Kristel, Elinor J. Sawyer, Anita Grigoriadis, Liping Fu, Marjanka K. Schmidt, Lindy L. Visser, Brian A. Menegaz, Michiel de Maaker, Timothy Hardman
Pure ductal carcinoma in situ (DCIS) is being diagnosed more frequently through breast screening programmes and is associated with an increased risk of developing invasive breast cancer. We assessed the clonal relatedness of 143 cases of pure DCIS an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d34124ca76de07a15115ddabc2f67e1e
https://doi.org/10.1101/2021.03.22.21253209
https://doi.org/10.1101/2021.03.22.21253209
Autor:
Simon J. Crabb, Gareth Owen Griffiths, Denise Dunkley, Nichola Downs, Mary Ellis, Mike Radford, Michelle Light, Josh Northey, Amy Whitehead, Sam Wilding, Claire Rooney, Carolina Salinas-Souza, Alison Jane Birtle, Vincent Khoo, Robert J. Jones
Publikováno v:
Journal of Clinical Oncology. 40:108-108
108 Background: The AKT pathway is frequently deregulated in mCRPC. ProCAID tested addition of capivasertib, a potent selective inhibitor of all three AKT isoforms (AKT1/2/3) to docetaxel chemotherapy vs. placebo plus docetaxel for mCRPC. The primary
Autor:
Carolina Salinas-Souza, Viviane Sonaglio, André Lopes Carvalho, Silvia Regina Caminada de Toledo, Beatriz de Camargo, Antonio Sergio Petrilli, André Luiz Vettore, Ana Carolina de Carvalho
Publikováno v:
OncoTargets and therapy
Viviane Sonaglio,1 Ana C de Carvalho,2 Silvia R C Toledo,3,4 Carolina Salinas-Souza,3,4 André L Carvalho,5 Antonio S Petrilli,3 Beatriz de Camargo,6 André L Vettore21Pediatrics Department, A C Camargo Hospital, São Paulo, Brazil; 2Biological Scien
Autor:
Renato de Oliveira, Maria Teresa de Seixas Alves, Indhira Dias Oliveira, Antonio Sergio Petrilli, Silvia Regina Caminada de Toledo, Carolina Salinas-Souza
Publikováno v:
Cytotechnology. 65:347-353
Osteosarcoma (OS) is the most frequent malignant bone tumour in children and adolescents. In metastatic patients, the most common site of metastasis is the lung. There are relatively few cell lines of metastatic OS reported in the literature and the